Last reviewed · How we verify
NCT07216508
Liver Transplant CGM
trial testing Libre 3+ in Liver Transplant in 40 participants. Currently enrolling.
5 October 2026
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 13 October 2025 |
| Primary completion | 5 October 2026 |
| Estimated completion | 5 October 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Libre 3+
Conditions studied
- Liver Transplant — all drugs for Liver Transplant →
- Post Transplant Diabetes — all drugs for Post Transplant Diabetes →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
18 and older, any sex, with Liver Transplant or Post Transplant Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07216508
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Transplant
Currently open trials in the same condition.
- NCT06254248 — Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
- NCT06832189 — EVR and EPO for Liver Transplant Tolerance · Phase 1 · recruiting
- NCT07086989 — Cardiovascular Risk in Children With Chronic Conditions Study · recruiting
- NCT06813508 — Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH · recruiting
- NCT06280950 — Expanding Liver Transplant Immunosuppression Minimization Via Everolimus · Phase 2 · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07216508 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 12 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07216508.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing